CLDX · Celldex Therapeutics, Inc.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-06-25 | Jain Rita |
Director |
Award↑
Filing footnotes — Non-Qualified Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. |
Non-Qualified Stock Option (right to buy)
|
26,000 |
| 2026-06-25 | Martin Samuel Bates |
SVP AND CFO |
Award↑
Filing footnotes — Incentive Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |
Incentive Stock Option (right to buy)
|
93,000 |
| 2026-06-25 | MARINO JAMES J |
Director |
Award↑
Filing footnotes — Non-Qualified Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. |
Non-Qualified Stock Option (right to buy)
|
26,000 |
| 2026-06-25 | PENNER HARRY JR |
Director |
Award↑
Filing footnotes — Non-Qualified Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. |
Non-Qualified Stock Option (right to buy)
|
26,000 |
| 2026-06-25 | Crowley Elizabeth |
SR. VP & CPDO |
Award↑
Filing footnotes — Incentive Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |
Incentive Stock Option (right to buy)
|
100,000 |
| 2026-06-25 | KELER TIBOR |
EXECUTIVE VP & CSO |
Award↑
Filing footnotes — Incentive Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |
Incentive Stock Option (right to buy)
|
115,000 |
| 2026-06-25 | Torres Denice |
Director |
Award↑
Filing footnotes — Non-Qualified Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. |
Non-Qualified Stock Option (right to buy)
|
26,000 |
| 2026-06-25 | Cohen Cheryl |
Director |
Award↑
Filing footnotes — Non-Qualified Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. |
Non-Qualified Stock Option (right to buy)
|
26,000 |
| 2026-06-25 | CONRAD HERBERT J |
Director |
Award↑
Filing footnotes — Non-Qualified Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. |
Non-Qualified Stock Option (right to buy)
|
26,000 |
| 2026-06-25 | Lawver Teri L |
SVP & Chief Commercial Officer |
Award↑
Filing footnotes — Incentive Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |
Incentive Stock Option (right to buy)
|
90,000 |
| 2026-06-25 | NEIL GARRY ARTHUR |
Director |
Award↑
Filing footnotes — Non-Qualified Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. |
Non-Qualified Stock Option (right to buy)
|
26,000 |
| 2026-06-25 | PEPIN RONALD |
SR. VP & CBO |
Award↑
Filing footnotes — Incentive Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |
Incentive Stock Option (right to buy)
|
20,000 |
| 2026-06-25 | Brownlie Keith L |
Director |
Award↑
Filing footnotes — Non-Qualified Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. |
Non-Qualified Stock Option (right to buy)
|
26,000 |
| 2026-06-25 | Young Diane C. |
SVP, CHIEF MEDICAL OFFICER |
Award↑
Filing footnotes — Incentive Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |
Incentive Stock Option (right to buy)
|
57,000 |
| 2026-06-25 | Heath-Chiozzi Margo |
SVP OF REGULATORY AFFAIRS |
Award↑
Filing footnotes — Incentive Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |
Incentive Stock Option (right to buy)
|
95,000 |
| 2026-06-25 | Cavanaugh Sarah |
SVP OF CORP AFFAIRS & ADMIN. |
Award↑
Filing footnotes — Incentive Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |
Incentive Stock Option (right to buy)
|
95,000 |
| 2026-06-25 | Jimenez Freddy A. |
SVP & GENERAL COUNSEL |
Award↑
Filing footnotes — Incentive Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |
Incentive Stock Option (right to buy)
|
93,000 |
| 2026-06-25 | Marucci Anthony S |
Director, PRESIDENT & CEO |
Award↑
Filing footnotes — Incentive Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |
Incentive Stock Option (right to buy)
|
375,000 |
| 2026-01-02 | Martin Samuel Bates |
SVP AND CFO |
Convert↑
|
Common Stock
|
4,817 |
| 2026-01-02 | Martin Samuel Bates |
SVP AND CFO |
Convert↓
Filing footnotes — Incentive Stock Option (Right to Buy) (Direct)
As of June 18, 2024, the option is fully vested. |
Incentive Stock Option (Right to Buy)
|
4,817 |
| 2025-12-15 | PEPIN RONALD |
SR. VP & CBO |
Convert↓
Filing footnotes — Incentive Stock Option (right to buy) (Direct)
As of June 19, 2023, the option is fully vested. |
Incentive Stock Option (right to buy)
|
11,000 |
| 2025-12-15 | PEPIN RONALD |
SR. VP & CBO |
Convert↓
Filing footnotes — Incentive Stock Option (right to buy) (Direct)
On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 200,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split. As of June 13, 2022, the option is fully vested. |
Incentive Stock Option (right to buy)
|
8,333 |
| 2025-12-15 | PEPIN RONALD |
SR. VP & CBO |
Convert↑
Filing footnotes — Common Stock (Direct)
Includes 764 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan. |
Common Stock
|
11,000 |
| 2025-12-15 | PEPIN RONALD |
SR. VP & CBO |
Convert↑
Filing footnotes — Common Stock (Direct)
On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 200,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split. Includes 764 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan. |
Common Stock
|
8,333 |
| 2025-12-04 | Jimenez Freddy A. |
SVP & GENERAL COUNSEL |
Sell↓
|
Common Stock
|
4,166 |
| 2025-11-13 | Wright Richard M. |
Insider |
Convert↓
Filing footnotes — Incentive Stock Option (Direct)
As of June 13, 2022, the option is fully vested. |
Incentive Stock Option
|
6,876 |
| 2025-11-13 | Wright Richard M. |
Insider |
Convert↓
Filing footnotes — Incentive Stock Option (Direct)
25% vested on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |
Incentive Stock Option
|
15,750 |
| 2025-11-13 | Wright Richard M. |
Insider |
Convert↓
Filing footnotes — Incentive Stock Option (Direct)
As of June 18, 2024, the option is fully vested. |
Incentive Stock Option
|
26,672 |
| 2025-11-13 | Wright Richard M. |
Insider |
Convert↑
|
Common Stock
|
6,876 |
| 2025-11-13 | Wright Richard M. |
Insider |
Convert↑
|
Common Stock
|
26,672 |
| 2025-11-13 | Wright Richard M. |
Insider |
Sell↓
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.05 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. |
Common Stock
|
49,298 |
| 2025-11-13 | Wright Richard M. |
Insider |
Convert↑
|
Common Stock
|
15,750 |
| 2025-11-10 | Lawver Teri L |
SVP & Chief Commercial Officer |
Other↑
|
No Securities Owned
|
0 |
| 2025-11-10 | Lawver Teri L |
SVP & Chief Commercial Officer |
Award↑
Filing footnotes — ISO (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. 25% vest on November 10, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |
ISO (right to buy)
|
100,000 |
| 2025-08-13 | Jimenez Freddy A. |
SVP & GENERAL COUNSEL |
Sell↓
Filing footnotes — Common Stock (Direct)
Includes 269 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan. |
Common Stock
|
341 |
| 2025-08-13 | Jimenez Freddy A. |
SVP & GENERAL COUNSEL |
Sell↓
|
Common Stock
|
430 |
| 2025-06-05 | Martin Samuel Bates |
SVP AND CFO |
Award↑
Filing footnotes — Incentive Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. 25% vest on June 5, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |
Incentive Stock Option (right to buy)
|
81,000 |
| 2025-06-05 | MARINO JAMES J |
Director |
Award↑
Filing footnotes — Non-Qualified Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. |
Non-Qualified Stock Option (right to buy)
|
16,500 |
| 2025-06-05 | NEIL GARRY ARTHUR |
Director |
Award↑
Filing footnotes — Non-Qualified Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. |
Non-Qualified Stock Option (right to buy)
|
16,500 |
| 2025-06-05 | Torres Denice |
Director |
Award↑
Filing footnotes — Non-Qualified Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Such option vests in three equal annual installments beginning June 5, 2026. |
Non-Qualified Stock Option (right to buy)
|
33,000 |
| 2025-06-05 | CONRAD HERBERT J |
Director |
Award↑
Filing footnotes — Non-Qualified Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. |
Non-Qualified Stock Option (right to buy)
|
16,500 |
| 2025-06-05 | PEPIN RONALD |
SR. VP & CBO |
Award↑
Filing footnotes — Incentive Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. 25% vest on June 5, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |
Incentive Stock Option (right to buy)
|
20,000 |
| 2025-06-05 | Jain Rita |
Director |
Award↑
Filing footnotes — Non-Qualified Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. |
Non-Qualified Stock Option (right to buy)
|
16,500 |
| 2025-06-05 | Cohen Cheryl |
Director |
Award↑
Filing footnotes — Non-Qualified Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. |
Non-Qualified Stock Option (right to buy)
|
16,500 |
| 2025-06-05 | Heath-Chiozzi Margo |
SVP OF REGULATORY AFFAIRS |
Award↑
Filing footnotes — Incentive Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. 25% vest on June 5, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |
Incentive Stock Option (right to buy)
|
82,000 |
| 2025-06-05 | Jimenez Freddy A. |
SVP & GENERAL COUNSEL |
Award↑
Filing footnotes — Incentive Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. 25% vest on June 5, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |
Incentive Stock Option (right to buy)
|
75,000 |
| 2025-06-05 | Cavanaugh Sarah |
SVP OF CORP AFFAIRS & ADMIN. |
Award↑
Filing footnotes — Incentive Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. 25% vest on June 5, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |
Incentive Stock Option (right to buy)
|
78,000 |
| 2025-06-05 | Brownlie Keith L |
Director |
Award↑
Filing footnotes — Non-Qualified Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. |
Non-Qualified Stock Option (right to buy)
|
16,500 |
| 2025-06-05 | Young Diane C. |
SVP, CHIEF MEDICAL OFFICER |
Award↑
Filing footnotes — Incentive Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. 25% vest on June 5, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |
Incentive Stock Option (right to buy)
|
72,000 |
| 2025-06-05 | Marucci Anthony S |
Director, PRESIDENT & CEO |
Award↑
Filing footnotes — Incentive Stock Option (right to buy) (Direct)
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. 25% vest on June 5, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |
Incentive Stock Option (right to buy)
|
300,000 |